{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05423340",
            "orgStudyIdInfo": {
                "id": "I 2588022"
            },
            "secondaryIdInfos": [
                {
                    "id": "U54CA228110",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/U54CA228110"
                }
            ],
            "organization": {
                "fullName": "Roswell Park Cancer Institute",
                "class": "OTHER"
            },
            "briefTitle": "Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems",
            "officialTitle": "A Randomized, Parallel-group Open-label Trial of ENDS Users Switching From Flavors of Potentially High-toxicity Profile to Flavors of Potentially Low-toxicity Profile (CRoFT_3.2)",
            "acronym": "CRoFT",
            "therapeuticArea": [
                "Other"
            ],
            "study": "effect-of-e-liquid-flavor-on-respiratory-symptoms-in-people-using-electronic-nicotine-delivery-systems"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-03",
            "studyFirstSubmitQcDate": "2022-06-13",
            "studyFirstPostDateStruct": {
                "date": "2022-06-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Roswell Park Cancer Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "University of Rochester",
                    "class": "OTHER"
                },
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                },
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches."
        },
        "conditionsModule": {
            "conditions": [
                "Electronic Cigarette Use"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 216,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Use Own Brand of Flavored Product",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will use their current flavor of e cigarettes for 90 days",
                    "interventionNames": [
                        "Other: E-cigarette Flavor"
                    ]
                },
                {
                    "label": "Use Provided Tobacco Flavor",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will use a new assigned flavor for 90 days",
                    "interventionNames": [
                        "Other: E-cigarette Flavor"
                    ]
                },
                {
                    "label": "Vaping Abstinence - use \"Tobacco Free\" Nicotine Pouches",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants will be asked to stop vaping for 90 days and instead only use the provided 'tobacco free' nicotine pouches.",
                    "interventionNames": [
                        "Other: Tobacco Free Nicotine Pouch"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "E-cigarette Flavor",
                    "description": "Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid",
                    "armGroupLabels": [
                        "Use Own Brand of Flavored Product",
                        "Use Provided Tobacco Flavor"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Tobacco Free Nicotine Pouch",
                    "description": "participants will use tobacco free oral nicotine pouches",
                    "armGroupLabels": [
                        "Vaping Abstinence - use \"Tobacco Free\" Nicotine Pouches"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Risk biomarkers of inflammation and oxidative stress as measured by ELISA",
                    "description": "Oxidative stress and inflammation in plasma using ELISA . A quantitative measure of expression (units:pg/mg) will be produced.",
                    "timeFrame": "Up to 90 days"
                },
                {
                    "measure": "Respiratory tract inflammation activity",
                    "description": "Exhaled Nitric Oxide (FeNo)l be measured in participants' breath using a FDA cleared monitor NIOX VERO (Aerocrine) according to ATS guidelines. FeNO has been used to monitor airway inflammation to account for persistent and/or high allergen exposure as a factor associated with higher levels of FeNO",
                    "timeFrame": "Up to 90 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Amount of recent flavored product use",
                    "description": "Assessed using the PhenX Toolkit which tracks tobacco use and asks subjects to retrospectively estimate product use,",
                    "timeFrame": "UP to 90 days"
                },
                {
                    "measure": "Flavor Preference questionnaire",
                    "description": "Personal flavor questionnaire to determine flavor preference when using ENDS.",
                    "timeFrame": "Up to 90 days"
                },
                {
                    "measure": "Frequency of flavored product use",
                    "description": "Questions from Wave 1 Adult PATH Survey to measure use and regularity of use flavored products",
                    "timeFrame": "Up to 90 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* ENDS users as determined by: (a) using banned flavored ENDS with nicotine such as fruit, candy, dessert flavors, and/or any product that indicates such flavors (b) using ENDS daily, regularly for the past 6 months (self-reported).\n* No smoking tobacco or using smokeless tobacco for the past 6 months.\n* Subjects should be free of acute respiratory illness within the proceeding 30 days prior to recruitment (self-reported).\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.\n* After receiving information regarding the NYS flavor ban individuals must not want to quit vaping or stop using their flavored product for the next 90 days.\n\nExclusion Criteria:\n\n* Individuals with health conditions and therapies that may affect immune responses and levels of inflammatory markers, including allergic rhinitis, aspirin/NSAID therapy, asthma, immunodeficiency (HIV or other), Guillain-Barre Syndrome, COPD, or fever/respiratory illness within 30 days prior to entry into study (self-reported).\n* Pregnant or nursing female participants (self-reported on telephone screener, pregnancy test on Visit#1)\n* Unable to communicate in English.\n* Unable or unwilling to follow protocol requirements.\n* Self-report having active, untreated medical/psychiatric conditions.\n* History of serious side effects from nicotine or from any nicotine replacement therapies.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Vulnerable populations, such as cognitively impaired adults, individuals who are not yet adults, pregnant women, and prisoners.\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.\n* After receiving information about the NYS flavor ban, participants who report that they are thinking about quitting or stop using their flavor within the next 90 days.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Maciej Goniewicz, PhD",
                    "role": "CONTACT",
                    "phone": "716-845-2300",
                    "email": "Maciej.Goniewicz@roswellpark.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Maciej Goniewicz, PhD",
                    "affiliation": "Roswell Park",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Roswell Park Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14206",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maciej Goniewicz, MD",
                            "role": "CONTACT",
                            "phone": "800-767-9355",
                            "email": "askroswell@roswellpark.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M15623",
                    "name": "Signs and Symptoms, Respiratory",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009538",
                    "term": "Nicotine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005731",
                    "term": "Ganglionic Stimulants"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018722",
                    "term": "Nicotinic Agonists"
                },
                {
                    "id": "D000018679",
                    "term": "Cholinergic Agonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12478",
                    "name": "Nicotine",
                    "asFound": "Assess",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4029",
                    "name": "Central Nervous System Stimulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M20796",
                    "name": "Nicotinic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                }
            ]
        }
    },
    "hasResults": false
}